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Abstract
Background: To compare the incidence and timing of toxicity associated with the use of a reduced dose of stavudine from
40 to 30 mg in first-line antiretroviral therapy (ART) for HIV treatment and to investigate associated risk factors.
Methods: Multicohort study including 23 HIV programs in resource-limited countries. Adults enrolled between January 2005
and December 2009. Four-year rates of all-cause and stavudine-specific toxicity were estimated. Multilevel mixed-effect
Poisson and accelerated failure models were used to investigate factors associated with toxicity and timing of diagnosis.
Findings: A total of 48,785 patients contributed 62,505 person-years of follow-up. Rate of all-cause toxicity was 7.80 (95%CI
7.59–8.03) per 100 person-years, but varied greatly across sites (range 0.41–21.76). Patients treated with stavudine 40 mg
had higher rates of toxicity (adjusted rate ratio [aRR] 1.18, 95%CI 1.06–1.30 during the first year of ART; and 1.51, 95%CI
1.32–1.71 during the second year). Women, older age, initial advanced clinical stage, and low CD4 count were associated
with increased toxicity rate ratios. Timing of lipodystrophy and peripheral neuropathy diagnosis were 12% and 13% shorter,
respectively, in patients treated with stavudine 40 mg than in those receiving 30 mg stavudine dose (P=0.03 and 0.07,
respectively).
Insterpretation: Higher rates of drug-related toxicity were reported in patients receiving stavudine 40 mg compared with
30 mg, and the time to toxicity diagnosis was shorter in patients treated with the higher dose. Higher rates of toxicity were
observed during the first two years of ART.
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Introduction
Stavudine is a dideoxynucleoside agent active against HIV. It is
widely used for HIV treatment in resource-limited countries due to
its low cost, availability in double and triple generic fixed-dose
combinations of antiretroviral (ARV) drugs, favorable early
tolerability, convenient drug administration, and minimal require-
ments for laboratory monitoring.
The main adverse effects associated with stavudine use are
symmetrical peripheral neuropathy and lipodystrophy. These are
dose-related [1–5] and the neuropathy is clinically indistinguishable
from primary HIV-related distal polyneuropathy [6,7]. Based on
findings from a systematic review of clinical trials showing
equivalent antiviral efficacy and some evidence of lower rates of
stavudine-related toxicity [8], in 2007 the World Health Organi-
zation (WHO) recommended decreasing the dose of stavudine-
containing first-line ARV therapy (ART) from 40 mg to 30 mg
twice daily for adults irrespective of body weight [9]. The
effectiveness of this strategy to reduce or delay the development of
toxicity has not been evaluated.
Although the WHO has recommended replacing stavudine-
based regimens with less toxic combinations in first-line ART,
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of newly treated patients in low- and middle-income countries [10]
because of lack of affordable alternative regimens [11]. Because
phasing out of stavudine is not likely to be adopted in the coming
years by several countries, WHO is currently assessing whether
further reducing stavudine dosage to 20 mg BID could achieve
and maintain adequate virologic efficacy while reducing the
incidence and intensity of mitochondrial toxicity.
To guide decision-makers and ensure dose optimization and
appropriate use of effective ARV regimens, it is important to
understand the safety profile of alternative dosing of stavudine and
the factors that contribute to the development of adverse reactions.
In this analysis we compared toxicity associated with stavudine
dose reduction from 40 mg to 30 mg BID for the treatment of
HIV infection and investigated risk factors for and timing of
toxicity diagnosis in 23 HIV programs supported by Me ´decins
Sans Frontie `res (MSF).
Materials and Methods
Cohort Selection and Study Population
We analyzed individual patient data from all active MSF-
supported HIV programs using the electronic FUCHIA monitoring
software (Epicentre, Paris, France), with a loss to follow-up rate
,20% at one year since ART start and with at least 50 patients
meeting the study selection criteria. All patients aged $15 years old
with no prior history of ART use and who started on a stavudine-
containing first-line ARV regimen between 1 January 2005 (date of
start of collection of ARV toxicity information) and 31
st December
2009 were included. Regimens were administered in the form of a
fixed-dose combination of ARVs. Because onset of stavudine-
related toxicity has been reported to happen between weeks 5 and
46 of treatment (22 weeks when 0.5 mg/kg/dose BID is used) [2],
the primary analysis used only information from patients who had
received a stavudine-based regimen for $3 months.
Data Collection and Definitions
At each consultation or hospitalization individual patient data
were prospectively collected using standardized forms and entered
into FUCHIA. Data collected included sex, age, date and type of
toxicity, dates of appointment and clinical visits, CD4 cell count
measurements, and date of ART start. No patient identifiers were
kept in the datasets analyzed.
The primary outcome was the first recorded toxicity diagnosis,
whether or not it led to a change of ART regimen (all-cause
toxicity). The secondary outcomes were specific stavudine-related
toxicity (first recorded diagnosis of lipodystrophy, polyneuropathy,
lactic acidosis, and/or pancreatitis), timing of toxicity diagnosis,
and toxicity leading to stavudine interruption. All toxicity events
were included regardless of severity grading, and definitions of
toxicity were based on the grading scale from the Division of
AIDS, National Institute of Allergy and Infectious Diseases,
version 1.0 December 2004.
Ethics
In agreement with health ministries, data were prospectively
collected. No patient identifiers were kept in the data sets analysed,
and proposals for analysis were approved by the International
Ethics Review Board of MSF. As advised by the National
Commission of Informatics and Liberties, given the context in
which MSF works, information for patients about the data
collection system in the health facility and its use is provided to
patients verbally at program inclusion instead of obtaining written
informed consent.
Statistical Analysis
Patient follow-up started at the beginning of ART and was right-
censored at the earlier of the following events: date of last clinical
visit with prescription of a stavudine-containing regimen, change
in stavudine dose, death, transfer, toxicity diagnosis, or 4 years. For
each patient, total stavudine exposure was calculated multiplying
the total number of days receiving a stavudine-containing regimen
by the daily dose of stavudine administered (in mg). Kaplan-Meier
methods were used to describe 4-year cumulative toxicity. Rates of
all-cause and specific toxicity (whether or not it led to stavudine
interruption) and rates of toxicity leading to stavudine interruption
with Poisson exact 95% confidence intervals (CI) were estimated at
6 months by stavudine dose group.
To investigate the association between toxicity and stavudine
exposure, and associations with other potential risk factors,
multilevel mixed-effect Poisson models with random effects at
cohort level were used to account for heterogeneity between
programs. This was done by including stavudine dose (30 and
40 mg), duration of stavudine exposure in years, and an interaction
term between these two variables in the models. Factors considered
in the analysis were: sex; age (centered and introduced as a
continuous variable), CD4 cell count (,50, 50–99, 100–199, $200,
and missing cells/ml), body mass index (BMI, ,16, 16–18.49,
18.50–24.99, $25, and missing kg/m
2), active tuberculosis disease,
and clinical WHO stage (1 or 2, 3, 4, and missing) at ART start;
period of toxicity diagnosis (yearly from 2005 to 2009); and
adherence (.95% and #95% incident missed appointments) [12].
Analyses restricted to the subgroup of patients with complete data
(BMI, clinical stage, and CD4 cell counts) were also performed.
Because the pathophysiological mechanisms responsible for the
development of toxicity are unclear and might vary for different
types of toxicity, accelerated failure time models were used to
investigate time to first diagnosed episode of neuropathy and
lipodystrophy, the two main types of stavudine-related toxicities
diagnosed. Delay in diagnosis was modeled using a log-normal
distribution for neuropathy and a Weibull distribution for
lipodystrophy. The choice of models was based on the study of
Cox-Snell and deviance residuals obtained when using different
distributions. Factors considered in the analyses were the same as
listed before, except for the exclusion of the period of toxicity
diagnosis and duration of drug exposure and the inclusion of the
year of ART start. In addition, the variable cohort was included as
a fixed effect in the model for neuropathy, and type of location
(rural, urban, and semi-urban) in the model for lipodystrophy,
given the smaller number of recorded events for this type of
toxicity. In sensitivity analyses, timing of toxicity was studied when
episodes of toxicity recorded within 3 months of ART use were
also included (1 lipodystrophy and 731 peripheral neuropathies).
This was done because HIV-related distal symmetric polyneurop-
athy is more frequently diagnosed in patients with advanced HIV
disease [13–15]; the two types of peripheral neuropathy are
clinically similar, often overlap, and are likely to result in additive
or synergistic effects; and because patients in our programs started
ART in late HIV disease.
All analyses were performed in Stata 11 (StataCorp, College
Station, TX, US).
Results
A total of 62,505 person-years of follow-up from 48,785 patients
treated in 23 HIV programs were analyzed (Table S1; Figure S1),
10,960 from patients who received stavudine 40 mg and 51,544
from patients treated with stavudine 30 mg. Sixty-seven per cent
were women and median age at ART initiation was 36 years
Toxicity Associated with Stavudine Dose Reduction
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e28112(Table 1). Median cumulative exposure to stavudine was
36,192 mg for patients treated with stavudine 40 mg and
22,709 mg for those who received stavudine 30 mg. Regardless
of stavudine dose, the majority of patients timely attended clinical
visits during follow-up (99.5% had an adherence index of $95%).
All-Cause Toxicity
All-cause toxicity during the first 4 years of ART use was
diagnosed in 4878 (10%) patients after a median of 13 months of
ART start (Table 2). Of these, 2234 (45.8%) patients interrupted
stavudine use. Overall all-cause toxicity rate was 7.80 per 100
person-years (95%CI7.59–8.03); but rates varied greatly across sites,
from 0.41 to 21.76 per 100 person-years. Cumulative probability of
toxicity was higher for patients who received high-dose stavudine
(FigureS2A).Four-yeartoxicityrateswere9.63per100person-years
(95%CI 9.07–10.23) in patients who received stavudine 40 mg and
7.41 (95%CI 7.18–7.65) in those treated with stavudine 30 mg.
The highest rates of all-cause toxicity were seen during the 6–12
month period after ART initiation (6–18 months period for patients
on stavudine 40 mg). For the two dose groups, toxicity rates during
the second and fourth years of stavudine exposure were similar or
higher than during the first year of treatment (adjusted rate ratios
[aRR] 1.23, 95%CI 1.08–1.41; and 0.73, 95%CI 0.35–1.55,
respectively, for 40 mg; and 0.96, 95%CI 0.89–1.04, and 1.06,
95%CI 0.83–1.33, respectively, for 30 mg; Figure 1A).
The rate of regimen interruption because of toxicity was 3.42
(95%CI 3.28–3.56). This was higher for patients who received
regimens containing stavudine 40 mg (5.28, 95%CI 4.87–5.71,
compared to 3.02, 95%CI 2.88–3.17 in patients treated with
stavudine 30 mg).
Specific Toxicity
A total of 4228 (9%) patients were diagnosed with specific
stavudine toxicity during the first 4 years of ART use after a
median of 13 months of ART start (Table 2). Toxicities diagnosed
during the first recorded episode were 3805 neuropathy, 274
lipodystrophy, 144 lactic acidosis, and 5 pancreatitis. Of patients
with recorded specific stavudine toxicity, 1753 interrupted
stavudine use (1362 had peripheral neuropathy, 252 lipodystro-
phy, 137 lactic acidosis and 2 pancreatitis). Overall toxicity rate
was 6.73 per 100 person-years (95%CI 6.53–6.94), but rates varied
greatly across sites, from 0 to 20.79 per 100 person-years. As with
all-cause toxicity, cumulative probability of toxicity was higher for
patients who received high-dose stavudine (Figure S2B).
Four-year specific stavudine toxicity rates were higher in
patients who received stavudine 40 mg than in those treated with
30 mg (8.00 compared to 6.46 per 100 person-years), and the
highest values were seen during the 6–12 month period after the
start of ART. Rates during the second and fourth years of
stavudine exposure were not statistically different from those
Table 1. Characteristics of ART patients by stavudine dose group.
d4T 40 mg d4T 30 mg Total
N=7,813 N=40,972 N=48,785
Median age, years [IQR] 37.3 [31.5–44.1] 35.2 [29.7–42.8] 35.6 [30.0–43.0]
Women (%) 4303 (55.1) 28,176 (68.8) 32,479 (66.6)
Year of ART start (%)
2005 2592 (33.2) 7000 (17.1) 9592 (19.7)
2006 3134 (40.1) 9132 (22.3) 12,266 (25.1)
2007–2009 2087 (26.7) 24,840 (60.6) 26,927 (55.2)
Clinical stage (%)
1/2 2713 (35.8) 10,517 (26.5) 13,230 (28.0)
3 3558 (46.9) 19,976 (50.4) 23,534 (49.8)
4 1316 (17.4) 9156 (23.1) 10,472 (22.2)
TB diagnosis at ART start (%) 629 (8.1) 4828 (11.8) 5457 (11.2)
Median weight, kg [IQR] 66.0 [62.0–71.5] 51.0 [46.0–56.0] 53.0 [47.0–60.0]
Median BMI, kg/m
2 [IQR] 23.7 [21.7–26.2] 19.5 [17.7–21.4] 20.1 [18.1–22.3]
CD4 cell count, cells/mL
Median [IQR] 144 [80–195] 132 [64–197] 135 [67–197]
,50 914 (14.7) 6309 (19.7) 7223 (18.9)
50 – 99 1088 (17.4) 5817 (18.2) 6905 (18.0)
100 – 199 2842 (45.5) 12,213 (38.1) 15,055 (39.3)
$200 1397 (22.4) 7710 (24.1) 9107 (23.8)
Median cumulative stavudine exposure, mg [IQR] 38,952 [23,340–58,191] 24,069 [13,247–38,972] 26,080 [14,134–42,638]
Adherence index
1
$95% 7761 (99.5) 40,672 (99.5) 48,433 (99.5)
,95% 43 (0.5) 222 (0.5) 265 (0.5)
Abbreviations: ART, combined antiretroviral therapy; BMI, body mass index; d4T, stavudine; IQR, interquartile range; TB, tuberculosis.
Note: 1549 with missing clinical stage at ART start; 372 with missing weight at ART start; 7768 with missing BMI at ART start; 10,495 with missing CD4 cell count at ART
start.
1Adherence index is calculated as the incidence of appointment attendance with no delay.
doi:10.1371/journal.pone.0028112.t001
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regimen interruption because of specific stavudine toxicity was
2.68 (95%CI 2.56–2.81); and it was higher for patients who
received regimens containing stavudine 40 mg (4.03, 95%CI
3.68–4.42, compared to 2.39, 95%CI 2.26-2.53).
Factors Associated with Stavudine Toxicity
During the first year of ART use, all-cause and specific
stavudine toxicity were more frequently diagnosed in patients who
received stavudine 40 mg than in those treated with 30 mg (aRR
1.18, 95%CI 1.06–1.30 and aRR 1.17, 95%CI 1.05–1.31,
respectively; Table 3). Compared to patients treated with low-
dose stavudine, those who used stavudine 40 mg had an increased
risk of toxicity during the first 2 years of exposure but this
association was reversed in the subsequent 2 years (Figure 2).
Women (aRR 1.18, 95%CI 1.11–1.26) and patients of older age
(aRR 1.05, 95%CI 1.04–1.05 per year increase) had increased
toxicity ratios. Advanced clinical stage (aRR 1.12, 95%CI 1.03–
1.23 for stage 4; compared to stage 1 or 2), presence of tuberculosis
at ART start (aRR 1.15, 95%CI 1.04–1.26), and low initial CD4
cell counts (aRR 0.93, 95%CI 0.83–1.03 for 50–99; aRR 0.86,
95%CI 0.78–0.94 for 100–199; and aRR 0.89, 95%CI 0.80–0.99
for $200; compared to ,50 cells/ml) were also associated with
increased toxicity ratios. Estimates for specific stavudine toxicity
were similar to those reported for all-cause toxicity, although the
association with specific toxicity was stronger for period of
exposure (Table 3). Results from analyses restricted to the
subgroup of patients with complete CD4 cell count, clinical stage,
and BMI data did not differ from those reported above (Table S2).
Timing of Neuropathy and Lipodystrophy Diagnosis
During the first 4 years of ART use, a total of 3,803 patients
were diagnosed with peripheral neuropathy and 321 with
lipodystrophy. Rates of lipodystrophy increased over time while
Table 2. Rates of toxicity per stavudine dosage group and time of stavudine exposure.
No. of
events
(%)
Months on
ART to
event [IQR]
Toxicity rate/
100 PY
(95% CI)
[3-6] month
toxicity rate/
100 PY (95% CI)
[6-12] month
toxicity rate/
100 PY
(95% CI)
[12-18] month
toxicity rate/
100 PY
(95% CI)
[18-24] month
toxicity rate/
100 PY
(95% CI)
[24-48] month
toxicity rate/
100 PY
(95% CI)
ALL-CAUSE TOXICITY
Stavudine
40mg
1056
(13.5)
15.1
[9.0-23.1]
9.63
(9.07-10.23)
6.01
(5.28-6.84)
n=227
13.22
(11.97-14.60)
n=387
13.33
(11.82-15.04)
n=264
9.56
(7.96-11.47)
n=115
5.88
(4.59-7.52)
n=63
Only SA 1044
(13.5)
15.1
[9.0-23.2]
9.57
(9.01-10.17)
5.94
(5.21-6.78)
n=223
13.12
(11.87-14.50)
n=382
13.27
(11.76-14.98)
n=262
9.49
(7.60-11.40)
n=114
5.88
(4.59-7.53)
n=63
Stavudine
30mg
3822
(9.3)
12.6
[6.9-20.6]
7.41
(7.18-7.65)
5.70
(5.37-6.04)
n=1109
10.20
(9.67-10.76)
n=1361
7.87
(7.29-8.49)
n=669
6.08
(5.43-6.80)
n=305
7.24
(6.55-8.01)
n=378
Only SA 3,682
(9.2)
12.6
[6.9-20.7]
7.31
(7.08-7.55)
5.74
(5.41-6.09)
n=1088
10.16
(9.62-10.72)
n=1317
7.42
(6.86-8.03)
n=616
5.77
(5.14-6.48)
n=286
7.22
(6.53-7.99)
n=375
Total 4878
(10.0)
13.0
[7.2-21.1]
7.80
(7.59-8.03)
5.75
(5.45-6.07)
n=1,336
10.74
(10.25-11.26)
n=1748
8.90
(8.35-9.49)
n=933
6.75
(6.13-7.43)
n=420
7.01
(6.39-7.70)
n=441
Total SA 4726
(9.9)
13.0
[7.1-21.2]
7.71
(7.50-7.94)
5.77
(5.47-6.09)
n=1311
10.70
(10.21-11.22)
n=1699
8.54
(8.00-9.13)
n=878
6.50
(5.89-7.17)
n=400
6.99
(6.37-7.68)
n=438
SPECIFIC TOXICITY
Stavudine
40mg
882
(11.3)
15.2
[9.1-23.3]
8.00
(7.49-8.55)
5.05
(4.39-5.82)
n=191
11.37
(10.21-12.65)
n=334
10.98
(9.61-12.53)
n=219
7.47
(6.09-9.18)
n=91
4.30
(3.23-5.72)
n=47
Only SA 871
(11.2)
15.2
[9.1-23.4]
7.94
(7.43-8.48)
5.01
(4.34-5.78)
n=188
11.26
(10.11-12.55)
n=329
10.91
(9.55-12.47)
n=217
7.40
(6.02-9.10)
n=90
4.30
(3.23-5.72)
n=47
Stavudine
30mg
3346
(8.2)
12.7
[7.0-20.7]
6.46
(6.25-6.68)
4.93
(4.62-5.25)
n=959
8.86
(8.37-9.37)
n=1186
7.02
(6.48-7.61)
n=601
5.39
(4.79-6.07)
n=273
6.17
(5.53-6.87)
n=327
Only SA 3,219
(8.1)
12.6
[6.9-20.9]
6.36
(6.14-6.58)
4.95
(4.64-5.28)
n=939
8.81
(8.31-9.33)
n=1146
6.63
(6.10-7.20)
n=554
5.10
(4.51-5.76)
n=255
6.16
(5.52-6.86)
n=325
Total 4228
(8.7)
13.1
[7.2-21.2]
6.73
(6.53-6.94)
4.95
(4.6-5.24)
n=1150
9.31
(8.85-9.79)
n=1520
7.77
(7.26-8.32)
n=820
5.79
(5.23-6.42)
n=364
5.85
(5.28-6.47)
n=374
Total SA 4090
(8.6)
13.1
[7.2-21.4]
6.64
(6.44-6.85)
4.96
(4.68-5.26)
n=1127
9.26
(8.80-9.74)
n=1475
7.45
(6.94-8.00)
n=771
5.55
(4.99-6.17)
n=345
5.84
(5.27-6.46)
n=372
Note: CI, confidence interval; IQR, interquartile range; PY, person-years of follow-up; SA, sub-Saharan Africa.
doi:10.1371/journal.pone.0028112.t002
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then decreased over time (Figure S3). Timing of lipodystrophy
diagnosis was 12% shorter in patients receiving stavudine 40 mg
than in those treated with 30 mg (P=0.03). Although the size of
the effect observed for polyneuropathy was similar (time reduction
of 13%), this association was of borderline significance (P=0.07).
Sensitivity analyses including toxicity events diagnosed within 3
months of ART start gave similar results, showing shorter timing
of lipodystrophy (12%, P=0.03) and polyneuropathy (11%,
P=0.01) associated with the use of high stavudine dose.
Discussion
In this large multicentric analysis of data from HIV-infected
adults treated with stavudine-containing first-line regimens in
resource-limited settings, we observed rates of all-cause toxicity of
7.80 per 100 person-years, but with large variation across cohorts.
The majority of toxicities reported were events commonly
associated with stavudine use. During the first and second years
of ART use, patients treated with stavudine 40 mg had rates of
toxicity 1.18 and 1.51 times higher, respectively, than those who
received the 30 mg dose. Nevertheless, this relationship was
reversed in subsequent years of treatment. Timing of toxicity
diagnosis was approximately 12% shorter in patients who received
the higher stavudine dose.
Previous longitudinal studies have reported 1-year Kaplan-
Meier estimates of incident peripheral neuropathy ranging from
10% to 36% of patients having started ART [16,17], and showed
higher percentages of diagnoses among patients with AIDS.
Lipodystrophy has also been frequently diagnosed in Indian
patients treated with stavudine for a median of 20 months (46%
had lipodystrophy and 27% lipoatrophy) [18]. Among HIV-
infected patients in Senegal, prevalence of lipodystrophy was 40%
for patients who had received stavudine for less than 3 years [19].
Overall estimates of toxicity incidence observed in our analysis fall
within the ranges of rates reported in previous studies, but large
differences in estimations were seen across sites. It is however likely
that we underestimated rates of toxicity because of underreporting
of less severe cases, especially of lipodystrophy and lactic acidosis,
and because complete neurological examination is not routinely
done in the programs. Subclinical cases of peripheral neuropathy
and those diagnosed in patients who did not complain of
symptoms are therefore likely to have been excluded from the
estimations.
Rates of toxicity associated with the two drug doses were higher
during the second than during the first year of therapy use, but
they decreased with longer time of follow-up, resulting in an
artificial protective effect among patients with long-term stavudine
exposure. Other studies have reported similar effects of drug
exposure for peripheral neuropathy [13,14], probably reflecting
patients who are more susceptible to the development of toxicity,
especially neuropathy, and who would develop symptoms rapidly
after the start of drug exposure.
During the first year of ART use, all-cause toxicity rate among
patients using stavudine 40 mg was 1.18 times higher than among
those treated with 30 mg, and estimates were similar when specific
stavudine toxicity was studied. Adjusted incidence rate ratios
increased with time of drug exposure over the first 2 years of ART
use, was lower during the third year and similar during the fourth
year. This finding together with the observation of a shorter delay in
toxicity diagnosis associated with use of regimens containing stavudine
40 mg provides evidence of the cumulative dose effect of this drug.
Findings from safety studies including small numbers of patients
have reported dose-related increases in peripheral neuropathy
[1,2,4], treatment discontinuation [5,20], reduction in body mass
fat and malar fat thickness [20], and lipoatrophy [3] associated
with a higher use of stavudine dose. In an open-label, 48-week
study among patients treated with stavudine 40 mg for a median
of 6 years, dose reduction to 30 mg led to improvement in
symptomatic neuropathy in 23% of patients and to a reduction in
lactate levels [21]. In contrast, a similar dose reduction or
substitution of stavudine by tenofovir had minor or no effect on
mitochondrial function in peripheral mononuclear cells in a study
[22]. In another study the increase in mtDNA content in
peripheral blood mononuclear of patients was not associated with
an improvement in lipoatrophy after 1 year of follow-up [23].
Patients with long exposure to stavudine might therefore never
completely recover or require long time periods to see improve-
ments in adverse events.
The increased rates of toxicity observed in women, patients of
older age, and those with advanced clinical disease or active
tuberculosis observed in our analysis are consistent with findings
reported from clinical studies. In a longitudinal study conducted in
Figure 1. Adjusted incidence rate ratios of toxicity for duration of stavudine exposure (in years), per dosage group. Figure note:
Estimates with 95% confidence intervals are derived from multilevel mixed-effect Poisson models with random effects at cohort level. Reference
category is the first year of therapy exposure.
doi:10.1371/journal.pone.0028112.g001
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acidosis diagnosis than men, but no difference was observed in
treatment-limiting lipodystrophy [24]. Other studies did not report
differences in prevalent [13] or incident peripheral neuropathy
[17] in men and women, but most previous studies include very
few numbers of women. The difference in risk of toxicity observed
in men and women could relate to differences in susceptibility or to
a higher level of adherence to therapy achieved by women and not
fully captured by the proxy adherence indicator based on missed
clinical appointments.
Higher risk of peripheral polyneuropathy in older patients has
also been reported in both pre-ART [25] and ART studies
[7,13,14,26] and could be related to longer exposure to HIV and/
or ARV drugs [27]. The increased risk of toxicity observed with
low CD4 cell counts has also been reported in studies conducted
before [25,28] and after the start of ART [13–15]. Prevalence
[15,16] and incidence [16,25] of peripheral neuropathy have also
been reported to be higher in patients with AIDS than among
non-AIDS patients; shorter time to diagnosis has been observed in
patients with history of AIDS diagnosis [17]; and higher risk of
Table 3. Associations between toxicity and individual level factors.
All-cause toxicity Specific stavudine toxicity
aIRR (95% CI) P-value aIRR (95% CI) P-value
Stavudine dose ,0.001 ,0.001
30 mg 1 1
40 mg 1.18 (1.06-1.30) 1.17 (1.05-1.31)
Time of drug exposure (year) ,0.001 ,0.001
11 1
2 0.96 (0.89-1.04) 0.98 (0.91-1.06)
3 0.88 (0.78-1.00) 0.86 (0.75-0.98)
4 1.05 (0.83-1.33) 1.00 (0.77-1.29)
Age, per 1 year increase 1.05 (1.04-1.05) ,0.001 1.05 (1.04-1.05) ,0.001
Sex ,0.001 ,0.001
Men 1 1
Women 1.18 (1.11-1.26) 1.16 (1.08-1.24)
Period of toxicity diagnosis ,0.001 ,0.001
2005 1 1
2006 1.92 (1.67-2.21) 2.23 (1.89-2.62)
2007 2.23 (1.94-2.56) 2.76 (2.36-3.24)
2008 1.83 (1.59-2.12) 2.16 (1.83-2.54)
2009 5.89 (4.49-7.74) 6.75 (4.92-9.27)
Clinical WHO stage 0.004 0.026
1/2 1 1
3 1.06 (0.99-1.14) 1.05 (0.97-1.14)
4 1.12 (1.03-1.23) 1.06 (0.97-1.17)
Tuberculosis diagnosis at ART start 0.005 0.012
No 1 1
Yes 1.15 (1.04-1.26) 1.14 (1.03-1.27)
BMI group, kg/m
2 ,0.001 ,0.001
,16 1 1
16.00-18.49 0.96 (0.85-1.08) 0.99 (0.87-1.13)
18.50-24.99 0.87 (0.77-0.97) 0.88 (0.78-1.00)
$25 1.10 (0.95-1.29) 1.16 (0.99-1.37)
CD4 cell count, cells/mL 0.006 0.001
,50 1 1
50–99 0.93 (0.83–1.03) 0.93 (0.83–1.04)
100 – 199 0.86 (0.78–0.94) 0.83 (0.75–0.91)
$200 0.89 (0.80–0.99) 0.87 (0.78–0.98)
Note: Age was centered; and missing values for BMI, clinical stage, and CD4 cell counts were included as a separate category. Adjusted incidence rate ratios [aIRR] of all-
cause toxicity for the interaction between duration of exposure and stavudine dosage were 1.28 (95% CI 1.10–1.49), 0.66 (95% CI 0.49–0.89), and 0.69 (95% CI 0.32–1.51)
for the second, third, and fourth years of exposure to stavudine 40 mg, respectively, compared to the first year of stavudine 30 mg. The corresponding aIRR of specific
toxicity were 1.14 (95% CI 0.97–1.34), 0.56 (95% CI 0.40–0.79), and 0.47 (95% CI 0.17–1.29), respectively. P value from likelihood rate ratio tests for association were
calculated across all categories of a given variable.
doi:10.1371/journal.pone.0028112.t003
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measured as an increase of the total neuropathy score, has been
associated with reduction in CD4 levels [29]. The identification of
advanced disease as a risk factor for toxicity could be explained by
misclassification of patients with primary HIV-associated neu-
ropathy as ART toxic neuropathy. These two forms of sensory
peripheral neuropathy are the most frequent neurological
disorders affecting HIV-infected patients [6]. Nevertheless,
because the main risk factor analysis only included patients who
were receiving stavudine-based therapy for at least 3 months and
episodes diagnosed after this time, patients with clinically
significant neuropathy diagnosed before would have not been
included in the calculation of toxicity rates. It is therefore
reasonable to attribute the observed toxic effect to stavudine. This
observation is consistent with findings from recent in vitro studies
that identified a threshold of 80% reduction of mtDNA through
mutation or depletion mechanism before tissue pathology
develops [30,31] and with a trial investigating the effect of
reducing the dose of stavudine on metabolic parameters and
reporting a correlation between mtDNA and CD4 count levels
[32]. It is also in agreement with researchers who hypothesized
that patients diagnosed with severe immunodeficiency would be
more susceptible to axonal injury and development of subsequent
distal sensitive neuropathy [27]. Furthermore, the observed
increased risk of toxicity in patients who had active tuberculosis
at the start of ART could be explained by concomitant use of
isoniazid and/or because of the severity of HIV disease of these
patients.
Residual confounding due to absence of information about
concomitant pathologies such as diabetes mellitus [13,14], vitamin
B12 deficiency, or alcoholism [32], or to treatment with other
neurotoxicdrugsmightpartlyaffectthe estimationsmadeinourrisk
factor analysis. Nevertheless, these factors are unlikely to have had
an important impact since major known confounding factors were
considered. Furthermore, results from sensitivity analyses including
only patients with complete clinical stage, CD4 count, and BMI
data did not differ from those presented in the main analysis.
This study was based on analysis of routine monitoring data
collected in several HIV programs. Although this study was
observational and dose allocation to patients was not random,
dosage was based on changes in WHO recommendations rather
than individualized patient management. Before 2009, patients of
low body weight were the patients who received 30 mg stavudine-
containing regimens. After 2009, the two drug dosages were
available for prescription in the programs until the stocks of
stavudine 40 mg stored in the pharmacies were finished. Patients
diagnosed with minor stavudine-related toxicity were the first ones
to be changed from 40 to 30 mg dose. Furthermore, the risk factor
analysis and comparison of the timing of toxicity diagnosis were
adjusted for major confounding factors reported in the literature.
Also, clinicians working in the programs were unaware that this
evaluation would be conducted. Because of the relatively long
length of study follow-up (4 years), the patterns of reporting
toxicity likely changed over time, based on the level of experience
and type of provider. This might have led to underestimation of
the toxicity ratios comparing the two dose groups, given that high
Figure 2. Adjusted incidence rate ratios of toxicity-related to stavudine dosage exposure (40 mg vs. 30 mg) per duration of
exposure (in years) and type of toxicity with 95% confidence intervals.
doi:10.1371/journal.pone.0028112.g002
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these effects, reported estimates were also adjusted for both period
of toxicity diagnosis and year of exposure.
In conclusion, in this study conducted in severely immunosup-
pressed patients, incidence of adverse events associated with the
use of stavudine was high, particularly during the first two years of
drug exposure. Although the use of high dose of stavudine (40 mg)
was associated with a higher rate of toxicity and shorter delay in
toxicity diagnosis, these findings highlight the need to use
alternative, better tolerated nucleoside reverse transcriptase
inhibitor drugs as recommended in current WHO guidelines.
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